Search

Displaying results 2011 - 2020 of 4300 in total
  1. Drug

    Tixocortol

    go.drugbank.com/drugs/DB09091
    ApprovedWithdrawn

    Tixocortol is a 21-thiol derivative of hydrocortisone classified as a class A corticosteroid. It is a synthetic steroid with topical anti-inflammatory properties without the systemic glucocorticoid and mineralocorticoid activities and to...

  2. Drug

    Icatibant

    go.drugbank.com/drugs/DB06196
    ApprovedInvestigational

    [A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema.

  3. Drug

    Periciazine

    go.drugbank.com/drugs/DB01608
    Approved

    Pericyazine, like other phenothiazines, is presumed to act principally in the subcortical areas, by producing what has been described as a central adrenergic blockade.

  4. Drug

    Lenacapavir

    go.drugbank.com/drugs/DB15673
    ApprovedInvestigational

    [L42995] On December 22, 2022, it was also approved by the FDA.[L44473] … [A244170, A244175, A244180, A244190] Lenacapavir was first globally approved on August 22, 2022 by the European Commission to treat adults with multi-drug resistant HIV infection.

  5. Drug

    Atenolol

    go.drugbank.com/drugs/DB00335
    ApprovedInvestigational

    Atenolol itself was developed early on in this history by Alvogen Malta under the trade name Tenormin and received FDA approval in September, 1981.

  6. Drug

    Cupric Chloride

    go.drugbank.com/drugs/DB09131
    Approved

    Cupric chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).

  7. Drug

    Ammonium chloride

    go.drugbank.com/drugs/DB06767
    ApprovedInvestigationalVet approved

    Ammonium chloride is an inorganic compound with the formula NH4Cl. It is highly soluble in water producing mildly acidic solutions.

  8. Drug

    Aducanumab

    go.drugbank.com/drugs/DB12274
    ApprovedInvestigational

    [L34420] Biogen enrolled patients in phase 3 clinical trials in 2015 but increased the size of the trials from 1350 patients to 1650 patients to maintain statistical power in the face of a high standard … [A235668,A235720] Clinical trials showed a 23% relative difference between the experimental and placebo groups as determined by CDR; however, this is equivalent to an absolute difference of 0.4/18.

  9. Drug

    Bretylium

    go.drugbank.com/drugs/DB01158
    Approved

    Recent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site.

  10. Drug

    Ritiometan

    go.drugbank.com/drugs/DB13267
    Approved

    Ritiometan is a nasal spray which is marketed by the name Nécyrane in France. It is indicated for use in viral rhinitis/ the common cold.